Celera's blood test detects lung cancer – study
This article was originally published in Clinica
Executive Summary
A nine-biomarker test under development by Celera to detect non-small cell lung cancer (NSCLC) has sensitivity and specificity of 92% and 93%, respectively, a validation study has shown. The biomarker panel also distinguished malignant cases from benign lung disease.